Metastases - Revision history

Michael at 18:56, 3 January 2023

2023-01-03T18:56:55Z

← Older revision		Revision as of 18:56, 3 January 2023
Line 111:		Line 111:
	*[[Basics]].		*[[Basics]].
	*[[Pulmonary lymphangitic carcinomatosis]].		*[[Pulmonary lymphangitic carcinomatosis]].
			*[[Lytic metastases]].

	=Reference=		=Reference=

Michael: wikify

2021-08-05T18:23:18Z

wikify

← Older revision		Revision as of 18:23, 5 August 2021
Line 10:		Line 10:
	[[Lymph node]] metastases are dealt with in the article ''[[lymph node metastases]]''.		[[Lymph node]] metastases are dealt with in the article ''[[lymph node metastases]]''.

	A handful of things have metastatic-like behaviour but are not malignant. Examples of benign things with metastatic-like behaviour are: benign metastasizing leiomyoma,<ref name=pmid15099894>{{Cite journal \| last1 = Pitts \| first1 = S. \| last2 = Oberstein \| first2 = EM. \| last3 = Glassberg \| first3 = MK. \| title = Benign metastasizing leiomyoma and lymphangioleiomyomatosis: sex-specific diseases? \| journal = Clin Chest Med \| volume = 25 \| issue = 2 \| pages = 343-60 \| month = Jun \| year = 2004 \| doi = 10.1016/j.ccm.2004.01.014 \| PMID = 15099894 }}</ref> [[endometriosis]], [[endosalpingiosis]] and benign nevus cells (in lymph nodes).<ref>{{Cite journal \| last1 = Cook \| first1 = MG. \| title = Benign melanocytic lesions mimicking melanomas. \| journal = Pathology \| volume = 36 \| issue = 5 \| pages = 414-8 \| month = Oct \| year = 2004 \| doi = 10.1080/00313020412331283842 \| PMID = 15370110 }}</ref>		A handful of things have metastatic-like behaviour but are not malignant. Examples of benign things with metastatic-like behaviour are: benign metastasizing leiomyoma,<ref name=pmid15099894>{{Cite journal \| last1 = Pitts \| first1 = S. \| last2 = Oberstein \| first2 = EM. \| last3 = Glassberg \| first3 = MK. \| title = Benign metastasizing leiomyoma and lymphangioleiomyomatosis: sex-specific diseases? \| journal = Clin Chest Med \| volume = 25 \| issue = 2 \| pages = 343-60 \| month = Jun \| year = 2004 \| doi = 10.1016/j.ccm.2004.01.014 \| PMID = 15099894 }}</ref> [[endometriosis]], [[endosalpingiosis]] and [[Nodal nevus\|benign nevus cells (in lymph nodes)]].<ref>{{Cite journal \| last1 = Cook \| first1 = MG. \| title = Benign melanocytic lesions mimicking melanomas. \| journal = Pathology \| volume = 36 \| issue = 5 \| pages = 414-8 \| month = Oct \| year = 2004 \| doi = 10.1080/00313020412331283842 \| PMID = 15370110 }}</ref>

	=Special types=		=Special types=

Michael: mamma

2018-09-28T15:43:21Z

mamma

← Older revision		Revision as of 15:43, 28 September 2018
Line 92:		Line 92:

	The tumour cells stain as follows:		The tumour cells stain as follows:
	POSITIVE: CK7, ER, PR, ~~MAMMOGLOBIN~~.		POSITIVE: CK7, ER, PR, MAMMAGLOBIN.
	NEGATIVE: CK20, TTF-1, CDX2, HER2, GCDFP.		NEGATIVE: CK20, TTF-1, CDX2, HER2, GCDFP.

Michael: /* Other */

2017-01-17T03:48:35Z

Other

← Older revision		Revision as of 03:48, 17 January 2017
Line 37:		Line 37:
	{{Main\|Testicular metastasis}}		{{Main\|Testicular metastasis}}
	{{Main\|Ovarian metastasis}}		{{Main\|Ovarian metastasis}}
			{{Main\|Urinary bladder metastasis}}

	===Brain===		===Brain===

Michael at 16:10, 3 May 2016

2016-05-03T16:10:32Z

← Older revision		Revision as of 16:10, 3 May 2016
Line 1:		Line 1:
	[[Image:Metastatic adenocarcinoma - cerebellum - intermed mag.jpg\|right\|250px\|thumb\|A [[brain metastasis]]. [[H&E stain]].]]		[[Image:Metastatic adenocarcinoma - cerebellum - intermed mag.jpg\|right\|250px\|thumb\|A [[brain metastasis]]. [[H&E stain]].]]
	'''Metastases''' are tumours that have spread from elsewhere and are separate from the initial (primary) lesion; usually, they are an ominous finding. ~~They may also be referred to as '''secondary tumours'''.~~		'''Metastases''' are tumours that have spread from elsewhere and are separate from the initial (primary) lesion; usually, they are an ominous finding.

	~~Seen from pathology~~, ''~~metastatic disease~~'' ~~and ''direct extension~~ of a tumour~~'' (on a biopsy) may be indistinguishable~~.		Metastases are not always obvious when encountered; thus, ''metastasis'' should be considered with every diagnosis of a [[cancer\|malignant tumour]].

	~~Metastases are not always obvious when encountered; thus~~, ''~~metastasis~~'' ~~should be considered with every diagnosis~~ of a ~~[[cancer\|malignant~~ tumour]].		Seen from pathology, ''metastatic disease'' and ''direct extension of a tumour'' (on a biopsy) may be indistinguishable. Collectively, they may also be referred to as '''secondary tumours'''.

	'''''[[Cancers of unknown primary]]''''' are dealt with in the ''[[cancer]]'' article. A general approach to undifferentiated tumours is given in the ''[[basics]]'' article under the heading '''''[[modified general morphologic DDx of malignancy]]'''''.		'''''[[Cancers of unknown primary]]''''' are dealt with in the ''[[cancer]]'' article. A general approach to undifferentiated tumours is given in the ''[[basics]]'' article under the heading '''''[[modified general morphologic DDx of malignancy]]'''''.

Michael: /* In-transit metastasis */

2016-02-25T15:18:47Z

In-transit metastasis

← Older revision		Revision as of 15:18, 25 February 2016
Line 17:		Line 17:
	{{Main\|Tumour deposits}}		{{Main\|Tumour deposits}}
	*It is called "in-transit", as it happens while the tumour is on the way to the regional lymph node.		*It is called "in-transit", as it happens while the tumour is on the way to the regional lymph node.
	*If a separate tumour nodule is close to the primary tumour, it is known as ''satellitosis''.		*If a separate tumour nodule is close to the primary tumour, it is known as ''[[satellitosis]]''.

	Note:		Note:

Michael at 15:10, 25 February 2016

2016-02-25T15:10:10Z

← Older revision		Revision as of 15:10, 25 February 2016
Line 2:		Line 2:
	'''Metastases''' are tumours that have spread from elsewhere and are separate from the initial (primary) lesion; usually, they are an ominous finding. They may also be referred to as '''secondary tumours'''.		'''Metastases''' are tumours that have spread from elsewhere and are separate from the initial (primary) lesion; usually, they are an ominous finding. They may also be referred to as '''secondary tumours'''.

	Seen from pathology, ''metastatic disease'' and ''direct extension of a tumour'' (on a biopsy) may be ~~distinguishable~~.		Seen from pathology, ''metastatic disease'' and ''direct extension of a tumour'' (on a biopsy) may be indistinguishable.

	Metastases are not always obvious when encountered; thus, ''metastasis'' should be considered with every diagnosis of a [[cancer\|malignant tumour]].		Metastases are not always obvious when encountered; thus, ''metastasis'' should be considered with every diagnosis of a [[cancer\|malignant tumour]].

Michael: /* Other */ +ovary

2016-01-28T05:37:43Z

Other: +ovary

← Older revision		Revision as of 05:37, 28 January 2016
Line 36:		Line 36:
	{{Main\|Peritoneal metastasis}}		{{Main\|Peritoneal metastasis}}
	{{Main\|Testicular metastasis}}		{{Main\|Testicular metastasis}}
			{{Main\|Ovarian metastasis}}

	===Brain===		===Brain===

Michael: /* IHC */

2015-10-24T03:03:25Z

IHC

← Older revision		Revision as of 03:03, 24 October 2015
Line 56:		Line 56:
	#The clinical impression is a metastasis.		#The clinical impression is a metastasis.
	#The suspected primary is ''not'' [[breast cancer\|breast]].		#The suspected primary is ''not'' [[breast cancer\|breast]].
	#*ASCO/CAP guidelines state that ''ER and PR (in breast recurrences) should always be re-tested''.<ref name=pmid20586616>{{Cite journal \| last1 = Hammond \| first1 = ME. \| last2 = Hayes \| first2 = DF. \| last3 = Dowsett \| first3 = M. \| last4 = Allred \| first4 = DC. \| last5 = Hagerty \| first5 = KL. \| last6 = Badve \| first6 = S. \| last7 = Fitzgibbons \| first7 = PL. \| last8 = Francis \| first8 = G. \| last9 = Goldstein \| first9 = NS. \| title = American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). \| journal = Arch Pathol Lab Med \| volume = 134 \| issue = 7 \| pages = e48-72 \| month = Jul \| year = 2010 \| doi = 10.1043/1543-2165-134.7.e48 \| PMID = 20586616 }}</ref>		#*ASCO/CAP guidelines state that ''ER and PR (in breast cancer recurrences) should always be re-tested''.<ref name=pmid20586616>{{Cite journal \| last1 = Hammond \| first1 = ME. \| last2 = Hayes \| first2 = DF. \| last3 = Dowsett \| first3 = M. \| last4 = Allred \| first4 = DC. \| last5 = Hagerty \| first5 = KL. \| last6 = Badve \| first6 = S. \| last7 = Fitzgibbons \| first7 = PL. \| last8 = Francis \| first8 = G. \| last9 = Goldstein \| first9 = NS. \| title = American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). \| journal = Arch Pathol Lab Med \| volume = 134 \| issue = 7 \| pages = e48-72 \| month = Jul \| year = 2010 \| doi = 10.1043/1543-2165-134.7.e48 \| PMID = 20586616 }}</ref>

	=Sign out=		=Sign out=

Michael: /* IHC */

2015-10-23T21:27:03Z

IHC

← Older revision		Revision as of 21:27, 23 October 2015
Line 55:		Line 55:
	#The morphology of the lesion is compatible with the established primary.		#The morphology of the lesion is compatible with the established primary.
	#The clinical impression is a metastasis.		#The clinical impression is a metastasis.
			#The suspected primary is ''not'' [[breast cancer\|breast]].
			#*ASCO/CAP guidelines state that ''ER and PR (in breast recurrences) should always be re-tested''.<ref name=pmid20586616>{{Cite journal \| last1 = Hammond \| first1 = ME. \| last2 = Hayes \| first2 = DF. \| last3 = Dowsett \| first3 = M. \| last4 = Allred \| first4 = DC. \| last5 = Hagerty \| first5 = KL. \| last6 = Badve \| first6 = S. \| last7 = Fitzgibbons \| first7 = PL. \| last8 = Francis \| first8 = G. \| last9 = Goldstein \| first9 = NS. \| title = American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). \| journal = Arch Pathol Lab Med \| volume = 134 \| issue = 7 \| pages = e48-72 \| month = Jul \| year = 2010 \| doi = 10.1043/1543-2165-134.7.e48 \| PMID = 20586616 }}</ref>

	=Sign out=		=Sign out=